NIH – National Institute of Allergy and Infectious Diseases
UM1AI068614
Edupuganti, S., Hurt, C. B., Stephenson, K. E., Huang, Y., Paez, C. A., Yu, C., Yen, C., Hanscom, B., He, Z., Miner, M. D., Gamble, T., Heptinstall, J., Seaton, K. E., Domin, E., Lin, B. C., McKee, K., Doria-Rose, N., Regenold, S., Spiegel, H., … Afemata, S. (2024). Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. The Lancet HIV. https://doi.org/10.1016/s2352-3018(24)00247-9
Grants:
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068619
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1016/s2352-3018(24)00247-9
PMID:
Journal:
Publication Date:
Data Source:
PubMed
Piepenbrink, M. S., Khalil, A. M., Chang, A., Mostafa, A., Basu, M., Sarkar, S., Panjwani, S., Ha, Y. H., Ma, Y., Ye, C., Wang, Q., Green, T. J., Kizziah, J. L., Erdmann, N. B., Goepfert, P. A., Liu, L., Ho, D. D., Martinez-Sobrido, L., Walter, M. R., & Kobie, J. J. (2024). Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variants. Npj Viruses, 2(1). https://doi.org/10.1038/s44298-024-00063-z
Grants:
P30CA013148
(NIH – National Cancer Institute)
R01AI161175
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
S10OD024978
(NIH – Office of the Director, National Institutes of Health)
Publication Type:
Article
Unique ID:
10.1038/s44298-024-00063-z
PMID:
Journal:
Publication Date:
Data Source:
PubMed
Source Link:
Record Created:
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
Janes, H., Fisher, L. H., Kee, J. J., Parameswaran, L., Goepfert, P. A., Falsey, A. R., Ludwig, J., Magaret, C. A., Gilbert, P. B., Kublin, J. G., Rouphael, N., Sobieszczyk, M. E., El Sahly, H. M., Baden, L. R., Grinsztejn, B., Walsh, S. R., Gray, G. E., Kotloff, K. L., Gay, C. L., … Huang, Y. (2024). Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae400
Subjects:
Coronavirus Disease 2019 Research
(OpenAlex Topic)
Factors Affecting Vaccine Hesitancy and Acceptance
(OpenAlex Topic)
Coronavirus Disease 2019
(OpenAlex Topic)
Grants:
U01AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148450
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148689
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148574
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1093/infdis/jiae400
PMID:
Journal:
Publication Date:
Data Source:
OpenAlex
Source Link:
Record Created:
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals
Fisher, L. H., Kee, J. J., Liu, A., Espinosa, C. M., Randhawa, A. K., Ludwig, J., Magaret, C. A., Robinson, S. T., Gilbert, P. B., Hyrien, O., Kublin, J. G., Rouphael, N., Falsey, A. R., Sobieszczyk, M. E., El Sahly, H. M., Grinsztejn, B., Gray, G. E., Kotloff, K. L., Gay, C. L., … Leathers, V. (2024). SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals. JAMA Network Open, 7(5), e2412835. https://doi.org/10.1001/jamanetworkopen.2024.12835
Subjects:
COVID-19
(MeSH)
Nasopharynx
(MeSH)
Viral Load
(MeSH)
SARS-CoV-2
(MeSH)
Coronavirus Disease 2019 Research
(OpenAlex Topic)
Diagnostic Methods for COVID-19 Detection
(OpenAlex Topic)
Epidemiology and Pathogenesis of Respiratory Viral Infections
(OpenAlex Topic)
Grants:
UM1AI069476
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068617
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148450
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068618
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI069496
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148689
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069534
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069496
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148576
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069423
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1001/jamanetworkopen.2024.12835
PMID:
Journal:
Publication Date:
Data Source:
OpenAlex
Record Created:
Mayer, B. T., Zhang, L., deCamp, A. C., Yu, C., Sato, A., Angier, H., Seaton, K. E., Yates, N., Ledgerwood, J. E., Mayer, K., Caskey, M., Nussenzweig, M., Stephenson, K., Julg, B., Barouch, D. H., Sobieszczyk, M. E., Edupuganti, S., Kelley, C. F., McElrath, M. J., … Huang, Y. (2024). Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV. Pharmaceutics, 16(5), 594. https://doi.org/10.3390/pharmaceutics16050594
Subjects:
Therapeutic Antibodies: Development, Engineering, and Applications
(OpenAlex Topic)
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
(OpenAlex Topic)
Role of Complement System in Immune Response
(OpenAlex Topic)
Grants:
UM1AI069412
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068619
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068618
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068617
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068613
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.3390/pharmaceutics16050594
PMID:
Journal:
Publication Date:
Data Source:
OpenAlex
Record Created:
Sherman, A. C., Tuan, J., Cantos, V. D., Adeyiga, O., Mahoney, S., Ortega-Villa, A. M., Tillman, A., Whitaker, J., Woodward Davis, A. S., Leav, B., Hirsch, I., Sadoff, J., Dunkle, L. M., Gilbert, P. B., Janes, H. E., Kublin, J. G., Goepfert, P. A., Kotloff, K., Rouphael, N., … Gay, C. L. (2024). Coronavirus Disease 2019 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized controlled Trials. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae192
Grants:
UM1AI148689
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069476
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069412
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148576
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069423
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148450
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1093/cid/ciae192
PMID:
DOI:
Journal:
Publication Date:
Data Source:
PubMed
Record Created:
Miner, M. D., deCamp, A., Grunenberg, N., De Rosa, S. C., Fiore-Gartland, A., Bar, K., Spearman, P., Allen, M., Yu, P.-C., Manso, B., Frahm, N., Kalams, S., Baden, L., Keefer, M. C., Scott, H. M., Novak, R., Van Tieu, H., Tomaras, G. D., Kublin, J. G., … Luke-Kilolam, A. (2024). Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial. EBioMedicine, 100, 104987. https://doi.org/10.1016/j.ebiom.2024.104987
Subjects:
AIDS Vaccines
(MeSH)
HIV Infections
(MeSH)
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
(OpenAlex Topic)
Immunobiology of Dendritic Cells
(OpenAlex Topic)
Prediction of Peptide-MHC Binding Affinity
(OpenAlex Topic)
Grants:
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
P30AI027757
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069534
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068618
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069554
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069412
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069439
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069511
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069496
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1016/j.ebiom.2024.104987
PMID:
Journal:
Publication Date:
Data Source:
OpenAlex
Record Created:
Reeves, D. B., Mayer, B. T., deCamp, A. C., Huang, Y., Zhang, B., Carpp, L. N., Magaret, C. A., Juraska, M., Gilbert, P. B., Montefiori, D. C., Bar, K. J., Cardozo-Ojeda, E. F., Schiffer, J. T., Rossenkhan, R., Edlefsen, P., Morris, L., Mkhize, N. N., Williamson, C., Mullins, J. I., … Edupuganti, S. (2023). High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-43384-y
Subjects:
HIV Infections
(MeSH)
HIV-1
(MeSH)
Grants:
R01AI150500
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
R37AI054165
(NIH – National Institute of Allergy and Infectious Diseases)
K25AI155224
(NIH – National Institute of Allergy and Infectious Diseases)
P30AI027757
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068613
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068617
(NIH – National Institute of Allergy and Infectious Diseases)
P30AI064518
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068618
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068619
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1038/s41467-023-43384-y
PMID:
Journal:
Publication Date:
Data Source:
PubMed
Source Link:
Record Created:
Sobieszczyk, M. E., Mannheimer, S., Paez, C. A., Yu, C., Gamble, T., Theodore, D. A., Chege, W., Yacovone, M., Hanscom, B., Heptinstall, J., Seaton, K. E., Zhang, L., Miner, M. D., Eaton, A., Weiner, J. A., Mayer, K., Kalams, S., Stephenson, K., Julg, B., … Montefiori, D. (2023). Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial. The Lancet HIV, 10(10), e653–e662. https://doi.org/10.1016/s2352-3018(23)00140-6
Subjects:
HIV Infections
(MeSH)
HIV-1
(MeSH)
Grants:
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068613
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068619
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068618
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068617
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069412
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069439
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1016/s2352-3018(23)00140-6
PMID:
Journal:
Publication Date:
Data Source:
PubMed
Source Link:
Record Created:
Karuna, S., Gallardo-Cartagena, J. A., Theodore, D., Hunidzarira, P., Montenegro-Idrogo, J., Hu, J., Jones, M., Kim, V., De La Grecca, R., Trahey, M., Karg, C., Takalani, A., Polakowski, L., Hutter, J., Miner, M. D., Erdmann, N., Goepfert, P., Maboa, R., … Corey, L. (2023). Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region. Journal of Global Health, 13. https://doi.org/10.7189/jogh.13.06020
Columbia Affiliation:
Subjects:
COVID-19
(MeSH)
Grants:
UM1AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068617
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069423
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.7189/jogh.13.06020
PMID:
Journal:
Publication Date:
Data Source:
PubMed
Source Link:
Record Created:
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials
Mena Lora, A. J., Long, J. E., Huang, Y., Baden, L. R., El Sahly, H. M., Follmann, D., Goepfert, P., Gray, G., Grinsztejn, B., Kotloff, K., Rouphael, N., Sobieszczyk, M., Walsh, S. R., Andriesen, J., Shah, K. A., Zhang, Y., Gilbert, P., Janes, H., Gay, C. L., … Wallace, S. E. (2023). Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. JAMA Network Open, 6(1), e2251974. https://doi.org/10.1001/jamanetworkopen.2022.51974
Subjects:
COVID-19
(MeSH)
Vaccines
(MeSH)
Coronavirus Disease 2019 Research
(OpenAlex Topic)
Immunogenicity of Biosimilar Therapeutics in Drug Development
(OpenAlex Topic)
Diagnostic Methods for COVID-19 Detection
(OpenAlex Topic)
Grants:
UM1AI148576
(NIH – National Institute of Allergy and Infectious Diseases)
P30AI045008
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI069424
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148685
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148689
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148684
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1001/jamanetworkopen.2022.51974
PMID:
Journal:
Publication Date:
Data Source:
OpenAlex
Record Created:
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
Gilbert, P. B., Huang, Y., deCamp, A. C., Karuna, S., Zhang, Y., Magaret, C. A., Giorgi, E. E., Korber, B., Edlefsen, P. T., Rossenkhan, R., Juraska, M., Rudnicki, E., Kochar, N., Huang, Y., Carpp, L. N., Barouch, D. H., Mkhize, N. N., Hermanus, T., Kgagudi, P., … Morris, L. (2022). Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nature Medicine, 28(9), 1924–1932. https://doi.org/10.1038/s41591-022-01953-6
Subjects:
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
(OpenAlex Topic)
Regulatory T Cell Development and Function
(OpenAlex Topic)
Natural Killer Cells in Immunity
(OpenAlex Topic)
HIV Infections
(MeSH)
HIV-1
(MeSH)
Grants:
P30AI064518
(NIH – National Institute of Allergy and Infectious Diseases)
P01AI131251
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068613
(NIH – National Institute of Allergy and Infectious Diseases)
P30AI027757
(NIH – National Institute of Allergy and Infectious Diseases)
R01AI152115
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068617
(NIH – National Institute of Allergy and Infectious Diseases)
R37AI054165
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068619
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068618
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
K25AI155224
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1038/s41591-022-01953-6
PMID:
Journal:
Publication Date:
Data Source:
PubMed
Record Created:
Phase 3 Safety and Efficacy of AZD1222 (CHADOX1 NCoV-19) Covid-19 Vaccine
Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., … Gonzalez-Lopez, A. (2021). Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. New England Journal of Medicine, 385(25), 2348–2360. https://doi.org/10.1056/nejmoa2105290
Subjects:
Grants:
UM1AI148574
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148450
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068618
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148684
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068636
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI148372
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068619
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1056/NEJMoa2105290
PMID:
Journal:
Publication Date:
Data Source:
Scopus
Record Created:
Astronomo, R. D., Lemos, M. P., Narpala, S. R., Czartoski, J., Fleming, L. B., Seaton, K. E., Prabhakaran, M., Huang, Y., Lu, Y., Westerberg, K., Zhang, L., Gross, M. K., Hural, J., Tieu, H.-V., Baden, L. R., Hammer, S., Frank, I., Ochsenbauer, C., Grunenberg, N., … McElrath, M. J. (2021). Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. Journal of Clinical Investigation, 131(16). https://doi.org/10.1172/jci146975
Subjects:
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
(OpenAlex Topic)
Vaginal Microbiome and Sexually Transmitted Infections
(OpenAlex Topic)
Diseases Related to Blood Group Variants
(OpenAlex Topic)
Antibodies, Monoclonal
(MeSH)
HIV Antibodies
(MeSH)
HIV Infections
(MeSH)
HIV-1
(MeSH)
Rectum
(MeSH)
Vagina
(MeSH)
Grants:
UM1AI069481
(NIH – National Institute of Allergy and Infectious Diseases)
P30AI064518
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068618
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069412
(NIH – National Institute of Allergy and Infectious Diseases)
P30AI045008
(NIH – National Institute of Allergy and Infectious Diseases)
ZIAAI005048
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1172/JCI146975
PMID:
DOI:
Journal:
Publication Date:
Data Source:
Scopus
Record Created:
Huang, Y., Seaton, K. E., Casapia, M., Polakowski, L., De Rosa, S. C., Cohen, K., Yu, C., Elizaga, M., Paez, C., Miner, M. D., Kelley, C. F., Maenza, J., Keefer, M., Lama, J. R., Sobieszczyk, M., Buchbinder, S., Baden, L. R., Lee, C., Gulati, V., … Goepfert, P. (2021). AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. Vaccine, 39(33), 4641–4650. https://doi.org/10.1016/j.vaccine.2021.06.066
Subjects:
Grants:
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
P30AI064518
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068618
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1016/j.vaccine.2021.06.066
PMID:
Journal:
Publication Date:
Data Source:
PubMed
Record Created:
Edupuganti, S., Mgodi, N., Karuna, S. T., Andrew, P., Rudnicki, E., Kochar, N., deCamp, A., De La Grecca, R., Anderson, M., Karg, C., Tindale, I., Greene, E., Broder, G. B., Lucas, J., Hural, J., Gallardo-Cartagena, J. A., Gonzales, P., Frank, I., … Sobieszczyk, M. (2021). Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. JAIDS Journal of Acquired Immune Deficiency Syndromes, 87(1), 671–679. https://doi.org/10.1097/qai.0000000000002639
Subjects:
Antibodies, Monoclonal
(MeSH)
Antibodies, Neutralizing
(MeSH)
HIV Antibodies
(MeSH)
HIV Infections
(MeSH)
Grants:
P30AI045008
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069534
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068619
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
ZIAAI005048
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068618
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI068618
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI068619
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1097/QAI.0000000000002639
PMID:
Publication Date:
Data Source:
Web of Science
Source Link:
Record Created:
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Corey, L., Gilbert, P. B., Juraska, M., Montefiori, D. C., Morris, L., Karuna, S. T., Edupuganti, S., Mgodi, N. M., deCamp, A. C., Rudnicki, E., Huang, Y., Gonzales, P., Cabello, R., Orrell, C., Lama, J. R., Laher, F., Lazarus, E. M., Sanchez, J., Frank, I., … Cohen, M. S. (2021). Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. New England Journal of Medicine, 384(11), 1003–1014. https://doi.org/10.1056/nejmoa2031738
Subjects:
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
(OpenAlex Topic)
Efficacy and Safety of Antiretroviral Therapy for HIV
(OpenAlex Topic)
Prevention and Treatment of HIV/AIDS Infection
(OpenAlex Topic)
Antibodies, Monoclonal
(MeSH)
HIV Antibodies
(MeSH)
HIV Infections
(MeSH)
HIV-1
(MeSH)
Grants:
UM1AI068635
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI154468
(NIH – National Institute of Allergy and Infectious Diseases)
P30AI027757
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068618
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068619
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069481
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069470
(NIH – National Institute of Allergy and Infectious Diseases)
ZIAAI005048
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068617
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069412
(NIH – National Institute of Allergy and Infectious Diseases)
P30AI045008
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069463
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069424
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI069476
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069436
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069469
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068613
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI068614
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI108568
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069496
(NIH – National Institute of Allergy and Infectious Diseases)
U01AI069436
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069476
(NIH – National Institute of Allergy and Infectious Diseases)
UM1AI069453
(NIH – National Institute of Allergy and Infectious Diseases)
Publication Type:
Article
Unique ID:
10.1056/nejmoa2031738
PMID:
Journal:
Publication Date:
Data Source:
PubMed